<DOC>
	<DOCNO>NCT02166268</DOCNO>
	<brief_summary>The clinical trial investigate efficacy Avanz Phleum pratense treatment rhinitis environmental challenge chamber .</brief_summary>
	<brief_title>Evaluation Efficacy Safety AVANZ® Phleum Pratense Grass Pollen-induced Allergic Rhinitis During Controlled Exposure Environmental Challenge Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Written inform consent Male female age 18 65 year The subject fulfill one follow criterion : Male Female , infertile Female childbearing potential , negative pregnancy test Moderatetosevere grass pollen induce rhinoconjunctivitis Positive skin prick test response ( wheal diameter ≥ 3 mm ) Phleum pratense Positive specific Immunoglobulin E ( IgE ) Phleum pratense ( ≥ IgE Class 2 ; ≥0.70 kilo Unit/L ) Minimum level rhinitis symptom grass pollen challenge , define total nasal symptom score least 6 ( 12 ) within 3hour grass pollen challenge perform baseline ECC visit The subject must willing able comply trial protocol Rhinoconjunctivitis cause ragweed , mugwort Alternaria alternate Rhinoconjunctivitis cause animal hair dander , house dust mites mould Clinical history uncontrolled asthma within 3 month prior screen Subjects reduce lung function force expiratory volume 1 second &lt; 70 % predict value adequate pharmacologic treatment Subjects asthma require treatment inhale corticosteroid outside grass pollen season Previous treatment immunotherapy grass pollen allergen cross react allergen within past 5 year Ongoing treatment allergenspecific immunotherapy product Symptoms treatment upper respiratory tract infection , acute sinusitis , acute otitis medium relevant infectious process randomisation baseline challenge Clinically relevant nasal polyp History paranasal sinus surgery History surgery nasal turbinates History anaphylaxis cardiorespiratory symptom ( immunotherapy , exercise induce , food allergy , drug idiopathic reaction ) History recurrent ( defined 2 episode ) generalise urticaria last 2 year History druginduced ( include immunotherapy ) facial angioedema family ( parent sibling ) history hereditary angioedema Any clinically relevant chronic disease ( ≥3 month duration ) ( e.g . cystic fibrosis , malignancy , malabsorption malnutrition , renal hepatic abnormality , diseases opinion investigator would interfere trial evaluation safety subject ) Systemic disease affect immune system ( e.g . insulindependent diabetes , autoimmune disease , immune complex disease , immune deficiency disease ) Immunosuppressive treatment ( ATC code L04 L01 ) within 3 month prior screen visit Currently treat tricyclic antidepressant , catecholamineO methyltransferase inhibitor and/or mono amine oxidase inhibitor Treatment antidepressant medication antihistaminic effect ( e.g . doxepin , mianserin ) Treatment antipsychotic medication antihistaminic effect ( e.g . chlorpromazine , levomepromazine , clozapine , olanzapine , thioridazine ) Treatment antiIgE drug ( e.g . omalizumab ) within 130 days/5 halflives ever long Treatment systemic and/or topical βblockers Use investigational drug within 30 days/5 halflives drug , ever long , prior screen History allergy , hypersensitivity intolerance excipient investigational drug ( except Phleum pratense ) Being immediate family investigator trial staff , define investigator's/staff 's spouse , parent , child , grandparent , grandchild History alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Allergic rhinoconjunctivitis</keyword>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Grass pollen</keyword>
</DOC>